Medtronic announced a three‑year partnership with digital‑health company Minze Health on November 12, 2025, to commercialize the Minze Diary Pod across the Europe, Middle East, and Africa (EMEA) region. The agreement will embed the automated bladder‑diary solution into the care pathway for patients receiving Medtronic’s InterStim sacral neuromodulation system for overactive bladder (OAB).
The Minze Diary Pod is a portable, Bluetooth‑enabled device that automatically records the time and volume of voided urine and transmits the data to a cloud‑based clinician portal via the Minze app. By providing objective, real‑time urinary behavior data, the pod improves clinician decision‑making and patient compliance compared with traditional paper diaries, and it is positioned to enhance the value proposition of Medtronic’s InterStim system. The integration is expected to drive higher adoption rates of the InterStim therapy and generate repeat revenue from device usage and support services.
Medtronic’s digital‑health strategy was highlighted in its Q3 FY25 earnings, where the company reported worldwide revenue of $8.292 billion, a 2.5% increase, and non‑GAAP diluted earnings per share of $1.64, up 7% from the prior year. CEO Geoff Martha emphasized that “new product innovation is fueling diversified growth across key health‑tech markets,” underscoring the company’s focus on expanding its digital portfolio. The Minze partnership aligns with that strategy by adding a data‑driven tool that complements Medtronic’s existing neuromodulation offerings.
The partnership positions Medtronic to capture a larger share of the growing digital‑health‑enabled OAB market, which is driven by increasing demand for objective monitoring solutions and the need for third‑line therapies after medication failure. While specific market‑share figures are not disclosed, the collaboration is expected to generate incremental revenue from device sales and ongoing support, and it strengthens Medtronic’s competitive stance against other digital‑health providers in the OAB space.
By integrating the Minze Diary Pod into the InterStim care pathway, Medtronic can improve patient outcomes through more accurate monitoring, potentially reducing the need for additional interventions. The partnership also supports the company’s growth trajectory in EMEA, where digital‑health adoption is accelerating. The three‑year commitment signals Medtronic’s long‑term investment in digital solutions that enhance its core neuromodulation products and create new revenue streams.
The collaboration represents a strategic move that expands Medtronic’s footprint in key international markets, reinforces its patient‑centric approach, and aligns with its broader goal of embedding digital health across its portfolio. The partnership is expected to contribute to Medtronic’s ongoing growth and to solidify its leadership position in the OAB market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.